Phase 2 Colorectal Cancer Trial, Recruiting NCT07283367 Sponsor: Hansoh BioMedical R&D Company Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 2 Colorectal Cancer Trial, Recruiting

NCT07283367
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older (male or female)
  • You have been officially diagnosed with advanced colorectal cancer confirmed by a laboratory test
  • You have at least one measurable area of cancer in your body that is not in the brain or spinal cord
  • Your cancer has been tested and does not have a specific genetic marker called MSI-H, and does not have a specific gene change called BRAF V600E mutation

Who may not be able to join:

  • You received anti-cancer drug treatment within the last 14 days, or certain other experimental or large-molecule cancer drugs within the last 28 days
  • You had radiation therapy to a small area within the last 2 weeks, or radiation covering a large part of your body or bone marrow within the last 4 weeks
  • You had major surgery within the last 4 weeks
  • You have recently taken certain medications that can affect how the body processes drugs (including specific enzyme blockers or boosters), or you would need to take them during the trial (confirm with trial site)
  • You are currently taking any medications known to affect heart rhythm in a specific way (called QT prolongation or torsade de pointes risk), or would need to take them during the trial
  • You received a live vaccine or live-attenuated vaccine within the last 28 weeks
  • You still have moderate or severe side effects (grade 2 or higher) left over from a previous cancer treatment, not including hair loss or certain nerve-related effects
  • You have poor blood cell counts or your liver or kidneys are not functioning well enough
  • You have a history of severe allergic reactions, serious reactions to infusions, or allergies to proteins made from human or mouse sources
  • You are allergic to any ingredient in the study drug combination being tested

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Hansoh BioMedical R&D Company
Registry
ClinicalTrials.gov
Start date
22 December 2025
Est. completion
31 December 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Maximum tolerated dose (MTD) or maximum applicable dose (MAD); Recommended phase 2 dose (RP2D); Objective response rate (ORR) as per RECIST v1.1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov